Novartis sues Lupin, Torrent over ANDAs filed for generic Exforge HCT
This article was originally published in Scrip
Executive Summary
Novartis has sued Lupin and Torrent Pharmaceuticals in district court regarding the filing of ANDAs with the US FDA, as the generics firms seek to bring to market their versions of the antihypertensive Exforge HCT (a combination of valsartan, amlodipine and hydrochlorothiazide) before patent expiry of US patents covering the product.